English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Anti-ganglioside serum titers were evaluated by ELISA in 150 patients with complete spinal cord lesion for 6 to 12 months (IgG monosialo GM1, IgM monosialo GM1, IgG asialo GM1, IgM asialo GM1, IgG disialo GD1b e IgM disialo GD1b) prior to treatment with GM1 100 mg/day i.m. Only 4 patients showed positive titers for anti-asialo-GM1 (IgM) antibodies . All patients were clinically examined during and after treatment. No important side effects were observed with GM1 therapy. These results suggest that GM1-ganglioside administration in patients with chronic spinal cord injury is safe. Soro de 150 pacientes com lesão medular completa com 6 a 12 meses de duração foi analisado para titulação de anticorpos anti-gangliosídeos pelo método ELISA (IgG monosialo GM1, IgM monosialo GM1, IgG asialo GM1, IgM asialo GM1, IgG disialo GD1b e IgM disialo GD1b). Somente 4 pacientes apresentaram títulos elevados de anticorpos contra asialo GM1 (IgM). Os demais apresentaram níveis de anticorpos abaixo dos valores de referência e foram todos tratados com GM1 na dose de 100 mg por dia i.m. Todos os pacientes foram acompanhados clinicamente durante e após o tratamento com GM1. Não foram observados efeitos adversos importantes com a medicação. O tratamento de pacientes lesados medulares crônicos com o gangliosídeo GM1 mostrou-se seguro, nos pontos sem positividade sorológica para anticorpos anti-GM1

Titration of serum anti-ganglioside antibodies in patients with chronic medular injury previous to treatment with GM1 ganglioside